Clinical Trial Update: Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update indicates Boundless Bio is recruiting participants for BBI-940, an oral kinesin degrader, in advanced or metastatic breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BBI-940

Snippet

Sponsor: Boundless Bio, Inc. | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 1 | Status: RECRUITING